Clinical trials: EBV Infection
Nasopharyngeal Carcinoma, EBV Infection
A Bidirectional Study in Exploring the Dynamic Changes of Plasma and Urine Metabolites of Nasopharyngeal Carcinoma.
The transformation process of nasopharyngeal carcinoma is complex, so it is particularly important to explore the relationship between various disease states on its clinical pathway.
- Trial name
- NCT05682703
- Testing
- Proteomics technology and liquid biopsy
- Where
- China
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Nanfang Hospital, Southern Medical University
Childhood Burkitt Lymphoma, Childhood Lymphoblastic Lymphoma
Studying Genes Associated With Non-Hodgkin Lymphoma in Young Patients
This research studies genes associated with non-Hodgkin lymphoma in young patients. Studying samples of blood and tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and…
- Trial name
- NCT01623856
- Testing
- laboratory biomarker analysis
- Where
- United States
- Volunteers
- 483 people, healthy volunteers welcome
- Sponsor
- Children's Oncology Group
EBV, Epstein-Barr Virus Infection
Epstein-Barr Virus (EBV) gH/gL/gp42-Ferritin Nanoparticle Vaccine With or Without gp350-Ferritin in Healthy Adults With or Without EBV Infection
Background: Epstein-Barr virus (EBV) is the primary cause of infectious mononucleosis, commonly known as mono. EBV infects more than 90% of the world s population.
- Conditions
- EBV, Epstein-Barr Virus Infection, Infectious Mononucleosis, Mono
- Trial name
- NCT06908096
- Testing
- EBV gp350-ferritin vaccine with ALFQ adjuvant, EBV gH/gL/gp42-ferritin nanoparticle vaccine with ALFQ adjuvant
- Where
- United States
- Volunteers
- 750 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Epstein-Barr Virus Infection
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants
The purpose of this study is to evaluate the safety and reactogenicity of mRNA-1195 in healthy participants.
- Trial name
- NCT05831111
- Testing
- mRNA-1195.1, mRNA-1195.2, mRNA-1189
- Where
- 34 sites in United States
- Volunteers
- 482 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Epstein-Barr Virus Infections
Protein Studies of the Epstein-Barr Virus in Ethnically Diverse Populations
This study will evaluate the ability of people of different ethnic backgrounds to develop immune responses against the Epstein-Barr virus (EBV).
- Trial name
- NCT00070785
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- National Institutes of Health Clinical Center (CC)
Epstein-Barr Virus Infection
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults
The main objective of Part A of this trial is to evaluate the safety and reactogenicity of mRNA-1189 in 18- to 30-year-old healthy adults, the main objective of Part B is to evaluate the safety and reactogenicity of mRNA-1189 in…
- Trial name
- NCT05164094
- Testing
- mRNA-1189
- Where
- 65 sites in United States
- Volunteers
- 867 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Epstein-Barr Virus Infections, Post-Transplant Lymphoproliferative Disorder
A Study of the Safety and Efficacy of EBV Specific T-cell Lines
This study evaluates the safety and efficacy of EBV-specific T-cell lines to treat patients suffering from high EBV viral titers not responding to standard of care therapies and to treat EBV-related lymphoma.
- Conditions
- Epstein-Barr Virus Infections, Post-Transplant Lymphoproliferative Disorder, Lymphoma
- Trial name
- EBV-TCL-01 (NCT02580539)
- Testing
- Group A, Group B
- Where
- Canada
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Dr. Jean-Sebastien Delisle, MD, PhD
Nasopharyngeal Carcinoma (NPC), Screening
Comparison and Strategy Optimization of Plasma EBV DNA and P85-Ab with VCA/EBNA1-IgA for Screening Nasopharyngeal Carcinoma in High-risk Areas
This study is a prospective, self-controlled, multicenter clinical trial. All participants will be tested for Epstein-Barr virus (EBV) associated biomarkers, including the two-antibody method (VCA-IgA and EBNA1-IgA), BNLF2b total…
- Conditions
- Nasopharyngeal Carcinoma (NPC), Screening, Epstein Barr Virus
- Trial name
- NCT06870435
- Testing
- Blood, nasopharyngeal swab and saliva, EBNA1-IgA, VCA-IgA, P85-Ab and EBV DNA, Novel screening biomarkers
- Where
- China
- Volunteers
- 68,649 people, healthy volunteers welcome
- Sponsor
- Ming-Yuan Chen